APAndrea Pennati

Andrea Pennati

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrea Pennati has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Jacques Galipeau

    Department of Medicine, School of Medicine and Public Health, University of Wisconsin–Madison, Wisconsin Institute for Medical Research, Madison, USA

    6 shared publications
  • Amar Yeware

    Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, USA

    3 shared publications
  • Catigan Hedican

    Department of Medicine, School of Medicine and Public Health, University of Wisconsin–Madison, Wisconsin Institute for Medical Research, Madison, USA

    3 shared publications
  • Shala Yuan

    Department of Medicine, School of Medicine and Public Health, University of Wisconsin–Madison, Wisconsin Institute for Medical Research, Madison, USA

    3 shared publications
  • Mahfuzur Rahman

    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

    2 shared publications
  • Rahul Das

    Department of Medicine, University of Wisconsin-Madison, Madison, WI, 53705, USA

    2 shared publications

Latest Publications

  • Open Access

    A CD40-Targeted IL-21 fusokine enables rapid generation of human IL-10⁺granzyme B⁺ regulatory B cells

    by Andrea Pennati, Shala Yuan, Rahul Das, Catigan Hedican, Amar Yeware, Jacques Galipeau

  • Open Access

    An autologous cell-based therapeutic vaccine expressing IL6/1 fusokine drives robust anti-tumor response against ovarian cancer

    by Sejal Sharma, Rahul Das, Andrea Pennati, Catigan Hedican, Lisa Barroilhet, Manish S. Patankar, Jacques Galipeau

    Background: Cytokines are immunomodulatory proteins that play central roles in regulating immune responses and represent attractive targets for cancer therapy. However, as single agents, cytokines have shown limited clinical benefit due to systemic toxicities and a short in vivo half-life. Our group has focused on engineering fusion cytokines (fusokines) that couple two cytokines into a single biologic to reprogram immune cell responses by enforcing non-canonical receptor engagement and signaling. A chimeric IL-6/IL-1β fusokine was engineered to test the hypothesis that enforced co-engagement of IL-6 and IL-1β signaling pathways would confer a gain-of-function phenotype in T cells and promote robust anti-tumor immunity. Here, we describe the immunomodulatory properties of IL6/1 fusokine and a method to deliver this fusokine to produce inhibition of ovarian tumor growth in a pre-clinical mouse model. Methods: Lentiviral vectors encoding murine or human IL6/1 were designed using Vector Builder and expressed in either HEK293, CHO or ID8-F3 (p53 −/- ) cells depending on the downstream experiment to be conducted. IL6/1 expression was validated by ELISA and flow cytometry. Effects of human IL6/1 (hIL6/1) on T cell function (proliferation, memory phenotype, activation induced apoptosis) were monitored by flow cytometry. For in vivo studies, ID8-F3 murine ovarian cancer cells expressing mouse IL6/1 (mIL6/1) were administered intraperitoneally (I.P.) as a cell-based therapy to C57BL/6 female mice bearing established ID8-F3 luciferase tumors. Tumor progression was monitored by bioluminescence (BLI) imaging, and overall survival was evaluated. Results: hIL6/1 significantly enhanced T cell survival and selectively promoted activation and expansion of CD45RO⁺ memory T cells. mIL6/1 expressing ID8-F3 cells (ID8IL6/1) demonstrated stable transduction and sustained cytokine secretion. In vivo, ID8IL6/1 cell therapy significantly reduced tumor growth and improved overall survival compared to control groups, with 2 of 8 mice achieving complete tumor clearance. Conclusion: These findings indicate that IL6/1 fusokine enhances T cell survival and proliferation while promoting memory responses. Engineered cancer cells (ID8-F3) expressing mIL6/1 fusokine induced a strong anti-tumor response when delivered as a therapeutic vaccine in ovarian cancer mouse model. What is already known on this topic: Fusokines are a class of bifunctional proteins designed to achieve synergistic immune modulation. Previous studies in our lab have shown fusokine exhibit gain-of-function immunomodulating activity. Individually, IL-6 and IL-1β are recognized for their roles in promoting T-cell proliferation and effector function. However, the potential for a fused IL-6/1 fusokine to reprogram the immune system and elicit a superior anti-tumor response in vivo in ovarian cancer model is not yet studied. What this study adds: This study develops a novel fusion cytokine (fusokine), combining IL-6 and IL-1β, and demonstrate robust activation of T cells. In a preclinical ovarian cancer model, engineered cancer cells expressing IL6/1 used as a therapeutic vaccine showed significant tumor reduction and improved overall survival. How this study might affect research, practice or policy: This study demonstrates that in comparison to individual cytokines, fusokines have greater potential to activate T cell function and when delivered as a cell therapy, achieve clear therapeutic efficacy in an ovarian cancer model. Further translational and clinical studies may enable the development of novel and more effective fusokine cell therapy approaches for patients with ovarian cancer.

  • Open Access

    Extracellular vesicles mediate intercellular transfer of PD-L1 and bystander T-cell suppression

    by Amar Yeware, Callum Brown, Chih-Chun Chang, Andrea Pennati, Jacques Galipeau

    Extracellular vesicles (EVs) carrying programmed death-ligand 1(PD-L1) on their membranes regulate immune responses. While membrane PD-L1 can be exchanged between tumor and immune cells through immune synapse, it remains unclear whether PD-L1 exchange occurs in non-immune cells. Here, we investigated the transfer of PD-L1 onto the surface of various recipient cells via EVs. Genetically engineered 293T PD-L1+ cells, when co-cultured with PD-L1neg isogenic or heterologous cells, showed a ~ 6 to 22-fold increase in surface PD-L1 on 100% of PD-L1neg bystander recipient cells. Purified PD-L1+ EVs retained competency to transfer PD-L1 to recipient PD-L1neg cell surfaces (> six fold increase). Importantly, transferred PD-L1 mediates binding to PD-1 and facilitates suppression of proliferation of activated T cells. Metabolically inert PD-L1neg 293T cells also acquired PD-L1 on their surfaces from PD-L1+ cells, or PD-L1+EVs, indicating a passive transfer mechanism independent of active cellular uptake. Overall, these findings reveal a distinct, passive and functional mechanism of PD-L1 transfer via EVs, defining previously underappreciated cell-physiological pathway that enables immune suppression and evasion by PD-L1neg somatic cells.


  • Open Access

    A CD40-Targeted IL-21 Fusokine Enables Rapid Generation of Human IL-10⁺Granzyme B⁺ Regulatory B Cells

    by Andrea Pennati, Shala Yuan, Rahul Das, Catigan Hedican, Amar Yeware, Jacques Galipeau

    Regulatory B cells (Bregs) have emerged as important modulators of immune homeostasis, complementing the classical roles of B cells in antibody production, antigen presentation, and provision of costimulatory signals and cytokines. Beyond promoting immunity, B cells can actively suppress inflammatory responses through specialized regulatory programs that limit effector T cell expansion and restrain pathogenic myeloid activation. These suppressive functions are mediated by mechanisms including secretion of IL-10, IL-35, and TGF-β, expression of inhibitory ligands, and release of granzyme B. However, Bregs are rare and heterogeneous in humans, typically comprising less than 1–2% of circulating B cells, and defects in their frequency or function are associated with autoimmune and inflammatory diseases. The scarcity of endogenous Bregs has driven interest in their ex vivo generation as a cellular immunotherapy. Although several strategies efficiently induce regulatory B cells in murine systems, translation to human B cells has been limited by inefficiency, lack of scalability, or reliance on poorly defined culture conditions. Consequently, a robust and clinically compatible approach for generating human Bregs has remained elusive. With human peripheral blood B cells as starting materiel, we show that a CD40 targeted IL-21 gain of function fusion protein in combination with TLR9 activation induces a stable regulatory phenotype characterized by IL-10 and granzyme B expression in more than 95% of input B-cells. These induced Bregs display a coordinated transcriptional program distinct from conventional activation, significantly suppress activated human T cell proliferation and modulate inflammatory myeloid responses in vitro. In mice with human T-cell driven xenoGVHD, transfusion of T-cell donor matched Bregs significantly improves survival. These data support the feasibility of Breg manufacturing at scale for use a cellular pharmaceutical.

  • Open Access

    Regulatory B cell CCL3 competency promotes disease resolution and oligodendrogenesis in experimental autoimmune encephalomyelitis

    by Andrea Pennati, Xingyi Tang, Catigan Hedican, Amar Yeware, Mahfuzur Rahman, Owen A. Zeitler, Shala Yuan, Jacques Galipeau

    Regulatory B cells (Bregs) contribute to immune homeostasis via IL-10–dependent and independent pathways. To dissect additional mediators, we investigated splenic derived GM-CSF/IL-15 fusokine (GIFT15)-induced Bregs in experimental autoimmune encephalomyelitis (EAE) using transcriptomics and functional validation. Bulk RNA-seq of splenic Bregs revealed upregulation of Ccl3, GzmB, and Il27 subunits compared to resting B cells. Functional studies showed that CCL3-deficient Bregs failed to suppress disease, whereas GzmB-deficient Bregs retained efficacy, and IL-27 receptor signaling in recipients was dispensable. Flow cytometry demonstrated that CCL3 expression correlated with FoxP3⁺ Treg and Tr1 expansion, along with CD206⁺ macrophage polarization. In the CNS, transient, tissue-dependent increases in oligodendroglial markers O4 and GalC were detected. Collectively, these findings identify CCL3 as a non-redundant effector of Breg-mediated protection, acting primarily through peripheral T-cell and myeloid remodeling, with secondary CNS impacts. These results highlight the translational potential of CCL3-competent, spleen-derived GIFT15 Bregs for therapeutic modulation of autoimmune demyelination.


  • Open Access

    Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models

    by Mahfuzur Rahman, Andrea Pennati, Tavus Atajanova, Trishna Debnath, Raad H. Allawi, Ross O. Meyers, Tracy J. Berg, Zafer Gurel, Nataliya V. Uboha, Michael F. Bassetti, et al.

    Pancreatic ductal adenocarcinoma (PDAC) is generally resistant to conventional immunotherapies due to its immunosuppressive tumor microenvironment (TME). We combine an innate cell–enriched product activated by interleukin-2 (IL-2) and zoledronic acid (ZA) (ICP IL2ZA ) with low-dose radiotherapy (RT) and monoclonal antibodies (mAbs) to overcome this immunosuppressive TME. ICP IL2ZA is composed of natural killer (NK) cell– and monocyte-enriched immune cells, activated ex vivo with IL-2 and ZA. ICP IL2ZA with RT and mAbs promotes antibody-dependent cellular cytotoxicity and phagocytosis against PDAC. In murine models of PDAC, RT and mAb combined with ICP IL2ZA derived from either murine or healthy human donors controlled tumor growth. RT amplifies ICP IL2ZA effectiveness by inducing NKG2D ligands on tumor cells, facilitating immune infiltration that leads to tumor growth control and extends survival without apparent toxicity. These results suggest that ICP IL2ZA can overcome limitations of traditional therapies by augmenting antitumor capabilities of endogenous immune cells, highlighting a promising autologous strategy for PDAC and other immunologically “cold” tumors.